Section 1 Short title
This Act may be cited as the “Accountability in Opioid Advertising Act”.
Accountability in Opioid Advertising Act
A BILL
To require the Food and Drug Administration to prioritize the promotional materials for drugs for serious, life-threatening diseases or conditions or substance use disorders, especially opioid drugs and drugs for medication-assisted treatment, in considering whether promotional materials are false or misleading.
Sec. 2 Promotional materials for drugs
In enforcing section 303(g) of the Federal Food, Drug, and Cosmetic Act (21 U.S.C. 333(g)) and otherwise ensuring that advertising and other promotional materials for drugs approved under section 505 of such Act (21 U.S.C. 355), including pursuant to section 503C of such Act (21 U.S.C. 353c), are not false or misleading, the Secretary of Health and Human Services shall give priority consideration to advertising and other promotional materials for drugs for serious, life-threatening diseases or conditions or substance use disorders, especially opioid drugs and drugs for medication-assisted treatment.